Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS).

OBJECTIVE Lung adenocarcinomas are divided into acinar, lepidic, papillary, micropapillary, and solid predominant subtypes according to the current World Health Organization (WHO) classification. We designed this retrospective study to demonstrate profiles of MUC expression (MUC1, MUC2, MUC5AC, and MUC6) of different histologic patterns within the same tumor among pulmonary adenocarcinomas and investigate correlations of MUC expression with clinicopathologic features. MATERIAL AND METHOD We analyzed the expression of mucins (MUC1, MUC2, MUC5AC, and MUC6) in a series of 99 resected lung adenocarcinomas, which included a total of 193 patterns (71 acinar, 30 lepidic, 25 papillary, 20 micropapillary, 34 solid and 13 mucinous) and calculated a final immune reactivity score (FIRS) per tumor. RESULTS MUC1 IRS scores were significantly higher in lepidic and solid patterns compared with mucinous patterns (p=0.013). MUC2 expression was seen only in three cases (1 acinar, 2 mucinous). MUC5AC and MUC2 expression was more common in mucinous patterns (p < 0.001 and p=0.028, respectively). MUC6 expression was only detected in seven patterns and the expression was weak. No significant difference was seen among histologic patterns for the staining scores of MUC6. Mucinous adenocarcinoma differed from other histologic subtypes regarding MUC1 and MUC5AC expression. Mucinous adenocarcinoma showed less MUC1 expression with lower IRS scores and higher MUC5AC expression. Tumor size (p=0.006), lymphatic invasion (p=0.018), vascular invasion (p=0.025), perineural invasion (p=0.019), MUC1 IRS scores (p=0.018), and MUC1 IRS scores > 8.5 (p=0.018) were significant predictors for lymph node metastasis. CONCLUSION An alternative scoring for MUC1 can be used as a predictor for lymph node metastasis regardless of the histologic subtype.

[1]  A. Franchi,et al.  Immunohistochemical profiling of mucins in sinonasal adenocarcinomas. , 2019, Pathology, research and practice.

[2]  I. van Seuningen,et al.  Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers. , 2017, Lung cancer.

[3]  J. Koo,et al.  Airway mucus: the good, the bad, the sticky. , 2009, Pharmacology & therapeutics.

[4]  A. Hartmann,et al.  Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. , 2008, Human pathology.

[5]  A. Ochiai,et al.  Comparison of the immunophenotypes of signet‐ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin , 2006, The Journal of pathology.

[6]  J. Voynow,et al.  Respiratory tract mucin genes and mucin glycoproteins in health and disease. , 2006, Physiological reviews.

[7]  P. Ellis,et al.  Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Y. Takeshima,et al.  Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. , 2004, American journal of clinical pathology.

[9]  E. Brambilla,et al.  Primary Mucinous (So-called Colloid) Carcinomas of the Lung: A Clinicopathologic and Immunohistochemical Study With Special Reference to CDX-2 Homeobox Gene and MUC2 Expression , 2004, The American journal of surgical pathology.

[10]  M. Goto,et al.  Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small‐size lung adenocarcinoma , 2004, Histopathology.

[11]  Michael A. Hollingsworth,et al.  Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.

[12]  M. Copin,et al.  Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. , 2001, Human pathology.

[13]  A. Harris,et al.  MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. , 1998, Journal of clinical pathology.

[14]  G. Pruneri,et al.  Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression. , 1998, Anticancer research.

[15]  J. Wesseling,et al.  A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. , 1996, Molecular biology of the cell.

[16]  Y. Kim,et al.  Membrane-bound (MUC1) and secretory (MUC2, MUC3, and MUC4) mucin gene expression in human lung cancer. , 1996, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[17]  Y. Kim,et al.  Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. , 1995, Cancer research.

[18]  Walsh,et al.  Prognostic significance of MUC1 epithelial mucin expression in breast cancer. , 1995, Human pathology.

[19]  A. Sonnenberg,et al.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components , 1995, The Journal of cell biology.

[20]  M. Hollingsworth,et al.  Developmental expression of mucin genes MUC1 and MUC2. , 1994, Journal of cell science.

[21]  C. Melief,et al.  Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. , 1993, Journal of immunology.

[22]  R. Dahiya,et al.  Heterogeneity of mucin gene expression in normal and neoplastic tissues. , 1993, Cancer research.

[23]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.